Y-mAbs Therapeutics (NASDAQ:YMAB) Issues Earnings Results

Y-mAbs Therapeutics (NASDAQ:YMAB) released its quarterly earnings results on Friday. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02), RTT News reports. Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. The firm had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. During the same quarter last year, the company earned ($0.18) earnings per share. Y-mAbs Therapeutics updated its FY 2024 guidance to EPS.

Y-mAbs Therapeutics Trading Down 0.5 %

NASDAQ:YMAB traded down $0.07 during trading hours on Friday, hitting $15.48. The company’s stock had a trading volume of 580,428 shares, compared to its average volume of 330,577. The stock has a market capitalization of $689.94 million, a P/E ratio of -27.64 and a beta of 0.68. The stock has a fifty day moving average of $14.11 and a 200-day moving average of $13.17. Y-mAbs Therapeutics has a 52-week low of $4.69 and a 52-week high of $20.90.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Morgan Stanley cut their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 13th. Finally, Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.14.

Insider Activity at Y-mAbs Therapeutics

In related news, COO Joris Wilms sold 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the transaction, the chief operating officer now owns 30,600 shares of the company’s stock, valued at $449,514. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $12.97, for a total transaction of $389,100.00. Following the transaction, the insider now owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Joris Wilms sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the transaction, the chief operating officer now directly owns 30,600 shares in the company, valued at approximately $449,514. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 100,000 shares of company stock valued at $1,338,100 over the last quarter. 22.50% of the stock is owned by insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.